Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aerosolised ciclosporin

Drug Profile

Aerosolised ciclosporin

Alternative Names: Cyclosporine aerosol; Cyclosporine inhalation solution; Pulminiq

Latest Information Update: 27 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer APT Pharmaceuticals Inc
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lung transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • No development reported Lung transplant rejection

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-III for Lung transplant rejection (Prevention) in USA and Canada (Inhalation)
  • 30 Sep 2008 Phase-III clinical trials in Lung transplant rejection in Canada (Inhalation)
  • 30 Sep 2008 APT Pharmaceuticals initiates enrolment in a phase III trial for Lung transplant rejection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top